Study of ipratropium bromide inhalation in stable asthma.
Article
Dans Anglais
| IMSEAR
| ID: sea-85322
ABSTRACT
An open two weeks short term trial of Ipratropium Bromide (IB) inhalation (0.02 mg per dose) was carried out in 20 stable asthamatics to study its efficacy and safety. Early significant rise in PEFR (P < 0.001) and FEV1 (P < 0.05) was observed after 15 min of IB inhalation and reached significant peak (P < 0.01) after 1 hour which was persistent beyond three hours after IB inhalation. No side effects were observed. It was concluded that Ipratropium Bromide Imhalation is safe and has efficient bronchodilatory effect on short term basis in stable asthmatics.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Asthme
/
Sécurité
/
Facteurs temps
/
Administration par inhalation
/
Bronchodilatateurs
/
Femelle
/
Humains
/
Mâle
/
Débit expiratoire de pointe
/
Capacité vitale
Type d'étude:
Étude observationnelle
/
Étude pronostique
langue:
Anglais
Année:
1995
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS